ANI Pharmaceuticals, Inc. Forecast, price target & analysts
ANI Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
ANI Pharmaceuticals, Inc. Classifications & Recommendation:
ANI Pharmaceuticals, Inc. Price Target
| Target Price | $86.70 |
| Price | $65.50 |
| Potential |
32.37%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target ANI Pharmaceuticals, Inc. 2026 .
The average ANI Pharmaceuticals, Inc. target price is $86.70.
This is
32.37%
register free of charge
$98.70
50.69%
register free of charge
$65.65
0.23%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend ANI Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ANI Pharmaceuticals, Inc. stock has an average upside potential 2026 of
32.37%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 614.38 | 801.86 |
| 26.20% | 30.52% | |
| EBITDA Margin | 11.49% | 25.53% |
| 48.17% | 122.26% | |
| Net Margin | -3.28% | 17.98% |
| 203.14% | 648.22% |
10 Analysts have issued a sales forecast ANI Pharmaceuticals, Inc. 2025 . The average ANI Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an ANI Pharmaceuticals, Inc. EBITDA forecast 2025. The average ANI Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 ANI Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average ANI Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.04 | 6.65 |
| 222.35% | 739.42% | |
| P/E | 9.84 | |
| EV/Sales | 2.35 |
10 Analysts have issued a ANI Pharmaceuticals, Inc. forecast for earnings per share. The average ANI Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
ANI Pharmaceuticals, Inc....
Current ANI Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | May 12 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Apr 21 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 12 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Apr 21 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Apr 11 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 17 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 05 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
